thalidomide has been researched along with Pancytopenia in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Pancytopenia: Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide is an important medication used in induction therapy for MM and is also used for maintenance therapy for standard risk patients." | 5.72 | Three Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL. ( Asawa, P; Chahine, Z; Lister, J; Sadashiv, S; Samhouri, Y; Vusqa, UT, 2022) |
| "A man in his late 60s who had received the first cycle of a chemotherapeutic regimen of ixazomib, lenalidomide, and dexamethasone for multiple myeloma presented to the dermatologic clinic with a 10-day history of fever and tender lesions on the neck and trunk." | 4.31 | Fever, Pancytopenia, and Tender Erythematous Plaques in a Patient With Multiple Myeloma. ( Katayama, S; Ota, M; Yamaga, M, 2023) |
| "Lenalidomide is an important medication used in induction therapy for MM and is also used for maintenance therapy for standard risk patients." | 1.72 | Three Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL. ( Asawa, P; Chahine, Z; Lister, J; Sadashiv, S; Samhouri, Y; Vusqa, UT, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vusqa, UT | 1 |
| Chahine, Z | 1 |
| Asawa, P | 1 |
| Sadashiv, S | 1 |
| Samhouri, Y | 1 |
| Lister, J | 1 |
| Yamaga, M | 1 |
| Katayama, S | 1 |
| Ota, M | 1 |
| Rao, K | 1 |
| Murthy, H | 1 |
| Muralidhar, NS | 1 |
| Rani, PK | 1 |
| Sukrisman, L | 1 |
| Mulansari, NA | 1 |
| Sudoyo, AW | 1 |
| Mesa, RA | 1 |
| Steensma, DP | 1 |
| Pardanani, A | 1 |
| Li, CY | 1 |
| Elliott, M | 1 |
| Kaufmann, SH | 1 |
| Wiseman, G | 1 |
| Gray, LA | 1 |
| Schroeder, G | 1 |
| Reeder, T | 1 |
| Zeldis, JB | 1 |
| Tefferi, A | 1 |
1 trial available for thalidomide and Pancytopenia
| Article | Year |
|---|---|
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
Topics: Adrenal Cortex Hormones; Aged; Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Ant | 2003 |
4 other studies available for thalidomide and Pancytopenia
| Article | Year |
|---|---|
Three Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL.
Topics: Aged; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pancytopenia; Thalidomide | 2022 |
Fever, Pancytopenia, and Tender Erythematous Plaques in a Patient With Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Erythema; Humans; Lenalidomide; Multi | 2023 |
Multiple myeloma masquerading as diabetic macular oedema.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Large-Core Needle; Bone Marrow; Cycl | 2018 |
A case with pancytopenia: the role of cytomorphology.
Topics: Bone Marrow; Cytodiagnosis; Female; Humans; Immunosuppressive Agents; Middle Aged; Myelodysplastic S | 2013 |